394 related articles for article (PubMed ID: 11435842)
1. A short-term, multicenter, randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence.
Davila GW; Daugherty CA; Sanders SW;
J Urol; 2001 Jul; 166(1):140-5. PubMed ID: 11435842
[TBL] [Abstract][Full Text] [Related]
2. Tolerability of 5 mg solifenacin once daily versus 5 mg oxybutynin immediate release 3 times daily: results of the VECTOR trial.
Herschorn S; Stothers L; Carlson K; Egerdie B; Gajewski JB; Pommerville P; Schulz J; Radomski S; Drutz H; Barkin J; Paradiso-Hardy F
J Urol; 2010 May; 183(5):1892-8. PubMed ID: 20303119
[TBL] [Abstract][Full Text] [Related]
3. Trospium chloride and oxybutynin hydrochloride in a german study of adults with urinary urge incontinence: results of a 12-week, multicenter, randomized, double-blind, parallel-group, flexible-dose noninferiority trial.
Zellner M; Madersbacher H; Palmtag H; Stöhrer M; Bödeker RH;
Clin Ther; 2009 Nov; 31(11):2519-39. PubMed ID: 20109997
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence.
Dmochowski RR; Davila GW; Zinner NR; Gittelman MC; Saltzstein DR; Lyttle S; Sanders SW;
J Urol; 2002 Aug; 168(2):580-6. PubMed ID: 12131314
[TBL] [Abstract][Full Text] [Related]
5. [Therapeutic effects of intrarectal administration of oxybutynin].
Radziszewski P; Borkowski A
Wiad Lek; 2002; 55(11-12):691-8. PubMed ID: 12715351
[TBL] [Abstract][Full Text] [Related]
6. Quantitative characterization of therapeutic index: application of mixed-effects modeling to evaluate oxybutynin dose-efficacy and dose-side effect relationships.
Gupta SK; Sathyan G; Lindemulder EA; Ho PL; Sheiner LB; Aarons L
Clin Pharmacol Ther; 1999 Jun; 65(6):672-84. PubMed ID: 10391673
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of oxybutynin transdermal system in spinal cord injury patients with neurogenic detrusor overactivity and incontinence: an open-label, dose-titration study.
Kennelly MJ; Lemack GE; Foote JE; Trop CS
Urology; 2009 Oct; 74(4):741-5. PubMed ID: 19628264
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of oxybutynin chloride topical gel for overactive bladder: a randomized, double-blind, placebo controlled, multicenter study.
Staskin DR; Dmochowski RR; Sand PK; Macdiarmid SA; Caramelli KE; Thomas H; Hoel G
J Urol; 2009 Apr; 181(4):1764-72. PubMed ID: 19233423
[TBL] [Abstract][Full Text] [Related]
9. Preliminary evaluation of a new controlled-release oxybutynin in urinary incontinence.
Radomski SB; Caley B; Reiz JL; Miceli PC; Harsanyi Z; Darke AC
Curr Med Res Opin; 2004; 20(2):249-53. PubMed ID: 15006020
[TBL] [Abstract][Full Text] [Related]
10. A double-blind randomized dose-response study comparing daily doses of 5, 10 and 15 mg controlled-release oxybutynin: balancing efficacy with severity of dry mouth.
Corcos J; Casey R; Patrick A; Andreou C; Miceli PC; Reiz JL; Harsanyi Z; Darke AC;
BJU Int; 2006 Mar; 97(3):520-7. PubMed ID: 16469019
[TBL] [Abstract][Full Text] [Related]
11. Transdermal oxybutynin: sticking to the facts.
Cartwright R; Cardozo L
Eur Urol; 2007 Apr; 51(4):907-14; discussion 914. PubMed ID: 17157979
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
[TBL] [Abstract][Full Text] [Related]
13. Randomized, placebo-controlled trial of the cognitive effect, safety, and tolerability of oral extended-release oxybutynin in cognitively impaired nursing home residents with urge urinary incontinence.
Lackner TE; Wyman JF; McCarthy TC; Monigold M; Davey C
J Am Geriatr Soc; 2008 May; 56(5):862-70. PubMed ID: 18410326
[TBL] [Abstract][Full Text] [Related]
14. Transdermal buprenorphine patches applied in a 4-day regimen versus a 3-day regimen: a single-site, Phase III, randomized, open-label, crossover comparison.
Likar R; Lorenz V; Korak-Leiter M; Kager I; Sittl R
Clin Ther; 2007 Aug; 29(8):1591-606. PubMed ID: 17919542
[TBL] [Abstract][Full Text] [Related]
15. An extended-release formulation of oxybutynin chloride for the treatment of overactive urinary bladder.
Goldenberg MM
Clin Ther; 1999 Apr; 21(4):634-42. PubMed ID: 10363730
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis.
Wagg A; Wyndaele JJ; Sieber P
Am J Geriatr Pharmacother; 2006 Mar; 4(1):14-24. PubMed ID: 16730617
[TBL] [Abstract][Full Text] [Related]
17. Dry mouth with conventional and controlled-release oxybutynin in urinary incontinence. The Ditropan XL Study Group.
Versi E; Appell R; Mobley D; Patton W; Saltzstein D
Obstet Gynecol; 2000 May; 95(5):718-21. PubMed ID: 10775736
[TBL] [Abstract][Full Text] [Related]
18. Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence.
Dmochowski RR; Sand PK; Zinner NR; Gittelman MC; Davila GW; Sanders SW;
Urology; 2003 Aug; 62(2):237-42. PubMed ID: 12893326
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics, efficacy, and safety of intravesical formulation of oxybutynin in patients with detrusor overactivity.
Lehtoranta K; Tainio H; Lukkari-Lax E; Hakonen T; Tammela TL
Scand J Urol Nephrol; 2002 Feb; 36(1):18-24. PubMed ID: 12002352
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of transdermal and oral oxybutynin in children with neurogenic detrusor overactivity.
Cartwright PC; Coplen DE; Kogan BA; Volinn W; Finan E; Hoel G
J Urol; 2009 Oct; 182(4):1548-54. PubMed ID: 19683731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
